IDH2 and glioblastoma: To detect any molecular marker as being associated with predictable disease diagnosis in glioblastoma, IDH-wildtype cases, an immunohistological analysis of p53 and Ki-67 was performed, along with an investigation of the status of the MGMT promoter.